Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02575794 · ClinicalTrials.gov registry record · Phase 1
Terameprocol in Treating Patients With Recurrent High Grade Glioma
A Phase 1 study of High Grade Glioma (III or IV), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 9
- Study locations
NCT02575794: Completed Phase 1 study of High Grade Glioma (III or IV), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT02575794 is a Phase 1 study of High Grade Glioma (III or IV) that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02575794, a Phase 1 study of High Grade Glioma (III or IV), has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 9
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of terameprocol in treating patients with high-grade glioma that has come back. Drugs used in chemotherapy, such as terameprocol, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Primary Outcome
To estimate the MTDs in terms of clinical toxicities, a modified continual reassessment method, based on that described by Piantadosi et al. will be employed. Dose escalation will be guided by observed clinical toxicity in 3 patients per dose cohort after the initial dose.
Conditions Studied
Interventions
- OTHER Pharmacological Study
- DRUG Terameprocol
Study Locations (9)
Pennsylvania
- Abrams Cancer Center of the University of Pennsylvania - Philadelphia
- Hillman Cancer Center at University of Pittsburgh Cancer Institute - Pittsburgh
Alabama
- UAB Comprehensive Cancer Center - Birmingham
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
New York
- Memorial Sloan-Kettering Cancer Center - New York
North Carolina
- Wake Forest University Comprehensive Cancer Center - Winston-Salem
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-05-03 |
| Est. Completion | 2023-10-04 |
| Phase | Phase 1 |
What the finished NCT02575794 record still lists
NCT02575794 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with High Grade Glioma (III or IV) appearing as the primary indexed condition, and to 2 interventions - of which Pharmacological Study is the first listed.
NCT02575794 lists 9 locations in 8 states (Pennsylvania, Alabama, Maryland).
Frequently Asked Questions
What is clinical trial NCT02575794 about?
NCT02575794 is a clinical study titled "Terameprocol in Treating Patients With Recurrent High Grade Glioma". This phase I trial studies the side effects and best dose of terameprocol in treating patients with high-grade glioma that has come back. Drugs used in chemotherapy, such as terameprocol, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from div...
What is the current status of trial NCT02575794?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-05-03. Estimated completion is 2023-10-04.
What conditions does trial NCT02575794 study?
This clinical trial studies the following conditions: High Grade Glioma (III or IV).
What interventions are being tested in trial NCT02575794?
The interventions under investigation include: Pharmacological Study (OTHER), Terameprocol (DRUG).
Who is sponsoring clinical trial NCT02575794?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02575794 being conducted?
This trial has 9 study locations across Alabama, Maryland, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02575794's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI